Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

Leukemia and Lymphoma

Volumn 53, Issue 10, 2012, Pages 2051-2053

  Nathwani, Nitya ^a   Krishnan, Amrita Y ^a   Huang, Qin ^a   Kim, Young ^a   Karanes, Chatchada ^a   Smith, Eileen P ^a   Forman, Stephen J ^a   Sievers, Eric ^b   Thomas, Sandra H ^a   Chen, Robert W ^a  

^a Department of Hematology/HCT ^*  (United States)

^b SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CD30 ANTIGEN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; ANTIGEN EXPRESSION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SCINTISCANNING; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MALE; MEDIASTINOSCOPY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ADULT; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; TREATMENT FAILURE; YOUNG ADULT;

EID: 84865749390     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.666543     Document Type: Letter

References (14)

1. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVDand alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin ' s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). JClin Oncol 2005;23:9208-9218.
2. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-623.
3. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin ' s disease: a randomised trial. Lancet 2002;359:2065-2071.
4. Yuen AR, Rosenberg SA, Hoppe RT, et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin ' s disease. Blood 1997;89:814-822.
5. Sureda A, Robinson S, Canals C, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin ' s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JClin Oncol 2008;26:455-462.
6. Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin ' s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 2008;93:257-264.
7. Chen R, Palmer JM, Popplewell L, et al. Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma. Ann Hematol 2011;90:803-808.
8. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1-14.
9. Re D, Thomas RK, Behringer K, et al. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105:4553-4560.
10. Chen R, Gopal AK, Smith SE, et al. Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116(SUPPL. 1): Abstract 283.
11. Chen RW, Gopal AK, Smith SE, et al. Results from a pivotal phase IIstudy of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). JClin Oncol 2011;29(SUPPL.): Abstract 8031.
12. Ghetie MA, Ghetie V, Vitetta ES. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant Blymphoma cells. Clin Cancer Res 1999;5:3920-3927.
13. Gan PP, McCarroll JA, Po' u ha ST, et al. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin. Mol Cancer Ther 2010;9:1339-1348.
14. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010;10:194-204.